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Abstract 5-azacytidine (AZA) has become standard treat-
ment for patients with higher-risk myelodysplastic syndrome
(MDS). Response rate is about 50% and response duration is
limited. Histone deactylase (HDAC) inhibitors are attractive
partners for epigenetic combination therapy. We treated 24
patientswithAZA (100mg/m
2, 5 days) plus valproate (VPA;
continuous dosing, trough serum level 80–110 μg/ml).
According to WHO classification, 5 patients had MDS, 2
had MDS/MPD, and 17 had acute myeloid leukemia (AML).
Seven patients (29%) had previously received intensive
chemotherapy, and five had previous HDAC inhibitor
treatment. The overall response rate was 37% in the entire
cohort but significantly higher (57%) in previously untreated
patients, especially those with MDS (64%). Seven (29%)
patients achieved CR (29%) and two PR (8%), respectively.
Hematological CR was accompanied by complete cyto-
genetic remission according to conventional cytogenetics
in all evaluable cases. Some patients also showed
complete remission according to FISH on bone marrow
mononuclear cells and CD34
+ peripheral blood cells, as
well as by follow-up of somatic mitochondrial DNA
mutations. Four additional patients achieved at least
marrow remissions. Factors influencing response were
AML (vs. MDS), marrow blast count, pretreatment,
transfusion dependency, concomitant medication with
hydroxyurea, and valproic acid (VPA) serum level. This
trial is the first to assess the combination of AZA plus
VPA without additional ATRA. A comparatively good CR
rate, relatively short time to response, and the influence of
VPA serum levels on response suggest that VPA provided
substantial additional benefit. However, the importance of
HDAC inhibitors in epigenetic combination therapy can
only be proven by randomized trials.
Introduction
In recent years, epigenetic therapy has become a treatment
optionforpatientswithhigher-riskmyelodysplasticsyndrome
(MDS) who are not considered candidates for intensive
induction chemotherapy or allogeneic stem cell transplanta-
tion (SCT). The demethylating agent 5-azacytidine (AZA)
can achieve substantial survival benefit for patients with
higher-risk MDS and patients with acute myeloid leukemia
(AML) who have a bone marrow blast count of 20–30%
(RAEB-T according to the FAB classification) (Fenaux et
al. 2009). Although complete response (CR) rates are not
higher than 10–20% (Fenaux et al. 2009; Silverman et al.
1994; Silverman et al. 2002, and Silverman et al. 2006),
almost half of the patients with intermediate-II or high-risk
disease according to IPSS (Greenberg et al. 1997)s h o w
hematological improvement. Responses are usually seen
A. Kuendgen (*): K. Nachtkamp: J. Neukirchen:A. Dienst:
R. Haas: U. Germing:N. Gattermann
Department of Hematology, Oncology and Clinical Immunology,
Heinrich-Heine-University,
Moorenstr. 5,
40225 Düsseldorf, Germany
e-mail: kuendgen@med.uni-duesseldorf.de
G. Bug: O. G. Ottmann
Department of Hematology and Oncology,
Johann Wolfgang Goethe University,
Frankfurt/Main, Germany
D. Haase: J. Schanz
Department of Hematology/Oncology,
Georg-August-University Göttingen,
Göttingen, Germany
B. Hildebrandt
Institute of Human Genetics, Heinrich-Heine-University,
Düsseldorf, Germany
Clin Epigenet (2011) 2:389–399
DOI 10.1007/s13148-011-0031-9only after several treatment cycles. Lengthy time to response
is problematic for patients with an aggressive course of
disease,particularlypatientswithAML.Results fromphase II
trials with azacytidine or decitabine suggest that only about
one third of such patients respond (Lubbert et al. 2008;
Maurillo et al. 2008). To further improve remission rates,
time to response and response duration, combinations of
AZA with other agents are being evaluated.
Since epigenetic treatment aims at reversing pathological
genesilencing,andDNAmethylationcooperateswithhistone
modification to control gene expression, it appears logical to
combine AZA with inhibitors of histone deacetylases.
Preclinical studies suggest that pharmacologic targeting of
both, DNA methyltransferases (DNMT) and histone deacety-
lases (HDAC), may result in synergistic anticancer activity
(Bhalla 2005;Y a n ge ta l .2005).
In 2001, two independent groups showed that the
antiepileptic drug valproic acid (VPA) also has HDAC
inhibitory activity and induces differentiation of malignant
myeloid cells, an ability that is enhanced by all-trans
retinoic acid (ATRA) (Göttlicher et al. 2001; Phiel et al.
2001). Stimulated by these findings, we studied the clinical
effect of VPA at serum concentrations of 50–100 μg/ml in
23 patients with AML or MDS as monotherapy or in
combination with (ATRA) (Kuendgen et al. 2004). The
pilot study yielded an overall response rate of 35%.
Interestingly, response rate was 44% for patients receiving
VPA monotherapy, while none of five patients receiving
VPA+ATRA from the start responded. Responses were
more frequent in lower-risk MDS, but some patients with
higher-risk MDS showed a decrease of their elevated blast
count. Follow-up of 122 patients confirmed the higher
response rates achieved in low-risk MDS. Only few patients
with high-risk MDS benefited from VPA monotherapy or
VPA+ATRA. Based on our experience with VPA
(Kuendgen et al. 2004; Kuendgen et al. 2006,a n d
Kuendgen and Gattermann 2007) and AZA (Fenaux et al.
2009), we embarked on evaluating the combination of the
two drugs in patients with MDS and AML.
Patients and methods
Study design
Primary endpoint of the study was the feasibility and safety of
a combination treatment with AZA plus VPA. Secondary
endpoints were overall and progression-free survival, as well
as hematological response rate according to revised Interna-
tional Working Group (IWG) criteria (Cheson et al. 2006).
Study treatment was initiated with AZA 100 mg/m
2/day for
5 days every 28 days administered subcutaneously. We
chose to investigate a 5-day schedule which is easier to
apply than the approved 7-day schedule (75 mg/m
2/day for
days 1–7) while providing almost the same cumulative dose
per cycle. Treatment with VPA was started on day 4. The
dosage of daily oral VPA was adjusted to achieve trough
serum concentrations between 80 and 110 μg/ml, i.e., in the
upper therapeutic range for antiepileptic treatment. Serum
VPA levels were measured with a commercially available
fluorescence polarization immunoassay (Abbott, Wiesbaden,
Germany). Response evaluation was performed by bone
marrow cytology, conventional cytogenetics, FISH on bone
marrow mononuclear cells (BM-FISH) and CD34
+ cells in
the peripheral blood (PB-CD34-FISH) (Braulke et al. 2010),
as well as analysis of somatic mitochondrial DNA mutations
(Wulfert et al. 2008). Treatment was continued as long as
neither significant side effects nor disease progression
occurred. Evaluation of treatment response included all
patients who had received at least one complete cycle of
study medication and was scheduled at least 1 year after
inclusion of the last patient. Two centers participated in the
trial, namely the University Hospital of Heinrich-Heine-
University, Düsseldorf and the University Hospital of Johann
Wolfgang Goethe-University, Frankfurt/Main.
Inclusion criteria
Patients included in the study had either
– primary MDS with poor-risk features: bone marrow
blast count ≥10% and/or poor-risk karyotype according
to IPSS (Greenberg et al. 1997)o r
– therapy-related, secondary MDS or AML, or
– AML according to WHO criteria (Harris et al. 1999)o r
– chronic myelomonocytic leukemia (CMML-II).
Inclusion criterion for all patients was relapse after,
ineligibility for, or refusal of intensive chemotherapy or
allogeneic SCT. Ineligibility for intensive treatment was
determined by the treating physician after thorough
discussion with the patient. Further inclusion criteria
included age ≥18 years, Karnofsky index >50%, negative
pregnancy test, and written informed consent according
to the Declaration of Helsinki. Patients were excluded if
they were eligible for intensive chemotherapy or allogeneic
S C T ,h a di m p a i r e dl i v e rf u n c t i on (bilirubin, ALT, and/or
AST >2× upper limit of normal) and/or reduced renal
function (creatinine >2.5× upper limit of normal),
previous liver failure, liver or pancreatic disease, or a
family history of liver failure, especially after treatment
with VPA, porphyria, or any kind of coagulopathy.
Patient characteristics
Between March and July 2007, 25 patients were enrolled,
of whom 24 received at least one complete cycle of therapy
390 Clin Epigenet (2011) 2:389–399and where thus evaluable for response. One patient could
not receive a full cycle of vidaza and did not receive VPA
due to very rapid disease progression. Median age was
73 years (59–87 years). According to FAB classification
(Bennett et al. 1982), 13 patients had MDS and 11 patients
suffered from AML. According to WHO (Harris et al.
1999), only 4 patients had MDS, 2 MDS/MPD, and 18
AML (6 de novo, 7 sAML/MDS, 5 AML/MDS therapy
related). Only nine patients (37%) had low-risk cytogenetics
according to IPSS (Greenberg et al. 1997), all of whom
showed a normal karyotype. Four patients (17%) had
intermediate-risk and 11 (46%) had high-risk cytogenetics,
including seven patients with aberrations of chromosome 7
(2 as single aberration, 2 with one additional abnormality,
and 3 as part of a complex karyotype). According to the
Grimwade definition for AML (Grimwade et al. 1998), none
of our patients had favorable cytogenetics, 12 (50%) had
intermediate-risk karyotypes and 10 patients (50%) had
adverse cytogenetics. Seventeen patients (71%) were con-
sidered ineligible for intensive chemotherapy, because of old
age (>75 years) (n=5), concomitant disease (n=6), or
adverse cytogenetics in patients >60 years of age (n=8).
Seven patients (29%) had previously received one (n=3) or
more (n=4) cycles of chemotherapy and had relapsed (n=5)
or were refractory (n=2). Five patients had previously
received treatment with an HDAC inhibitor (LBH589, n=3;
VPA, n=2). Patient characteristics are summarized in Table 1.
Statistical analysis
The product-limit method was used to estimate the
probability of survival. Survival was measured from start
of treatment to time of death. Survival curves were
compared using the log-rank test. Clinical and hematolog-
ical parameters of patients at the time of treatment were
compared using the chi-square test with Yates correction
and the Wilcoxon rank-sum test. Parameters that were
correlated with response were analyzed using logistic
regression and stepwise multivariate regression method of
Cox.
Results
Hematological response
Of the 24 patients evaluable for response, 7 achieved
cytological CR (29%) and two had PR (8%), giving an
overall response rate of 37%. All these patients showed
hematologic improvement. One CR was a CRi (with
incomplete recovery of platelets to less than 100,000/μl),
and in five cases dysplastic features persisted (CRdys). In
Table 1 Patient characteristics
Characteristic No.
Median age/years (range) 73 (59–87)
Gender (n=)
Male/female 19/5
Diagnosis (FAB) (n=)
RAEB 8
RAEB-T 3
CMML 2
AML 11
Diagnosis (WHO) (n=)
RAEB II 4
CMML II 2
AML, de novo 6
sAML/MDS 7
AML/MDS, therapy-related 5
IPSS-risk group (n=)
Intermediate II 5
High 9
Karyotype-risk (IPSS) (n=)
Good 9
Intermediate 4
Poor 11
Karyotype risk (AML
1)( n=)
Good 0
Intermediate 12
Poor 12
Karyotype (n=)
Normal 7
Abnormal 17
Median marrow blast count (%) 18 (1–80)
Pre-treatment (n=)
Intensive chemotherapy 1
Hydroxyurea 3
LBH-589 3
VPA (+/− ATRA) 2
Growth factors 2
None 2
Transfusion dependency
Yes/no 19/5
Median WBC/μl 2,245 (400–32,000)
WBC>10.000 (n=) 5
WBC<1,800 20
WBC<500 7
Median platelet count/μl 57,000 (5,000–252,000)
Platelets<100,000 (n=) 17
Platelets<30,000 9
FAB French–American–British classification, WHO World Health
organization classification, IPSS International Prognostic Scoring
System, AML acute myeloid leukemia, VPA valproic acid, ATRA all-
trans retinoic acid, WBC white blood count. 1 Grimwade 1998
Clin Epigenet (2011) 2:389–399 391addition to these nine patients with CR/PR, four patients
showed decreasing marrow blasts (three complete marrow
responses and one reduction from 34 to 8%), though
without hematologic improvement. These cases were not
considered as responders.
Interestingly, patient 14 with sAML/MDS, whose marrow
blasts decreased from 22 to 2% and who developed Coombs-
negative hemolysis, responded well to erythropoietin which
was started after the official end of the study (cycle 24).
Despite a relatively high endogenous Epo level of 584 mU/l,
the patient became transfusion independent (maximum
hemoglobin 13.6 g/dl). After cycle 24, the blast count
increased to 22% and then 50%. Surprisingly, peripheral
blood counts remained stable and the patient was transfusion-
independent for another 8 months despite full-blown relapse.
Cytogenetic response
In the six evaluable patients, hematological CR or PR was
always accompanied by complete remission as assessed by
conventionalcytogenetics(CgCR).The cytogenetic diagnosis
of the responders (+21; complex including monosomy 7; +8;
del(7q); −7 plus dup(1q); del(20q)) included three poor-risk
karyotypes.
Cytogenetic responses were also analyzed by FISH on
bone marrow mononuclear cells (BM-FISH) and CD34
+
cells in the peripheral blood (PB-CD34-FISH). Only the
patient with CRi did not have BM-FISH. In the other five,
complete remission was confirmed in four, while in one
patient, 6% cells with monosomy 7 persisted among BM-
MNC. However, in this patient, no aberrant cells were
detectable by PB-CD34-FISH. Among the six patients with
CgCR by conventional cytogenetics, four also showed
CgCR on analysis of PB-CD34-FISH, while two achieved
only CgPR (91→5→29%, and 79→1%).
Patient no. 6 showed an interesting development. Within
2 cycles, he achieved complete cytomorphologic remission.
After 5 cycles, he also showed CgCR on conventional
cytogenetics and BM-FISH. At that time, 32% of his PB-
CD34
+ cells still showed del(7q) (from an initial 91%). After
9 cycles, the proportion had fallen to 5%. After the first
2 cycles of treatment, an additional clone characterized by
loss of the Y chromosome was detected in the marrow,
which had not been described prior to study treatment
and increased to 53% of metaphases after 5 cycles.
Thereafter, that clone decreased slowly to 0%, in parallel
to an increase of del(7q) cells. A third clone was
observed after 13 cycles exhibiting complete monosomy
7. Cytologically, the patient showed only a borderline
blast count of 5% after 17 cycles. The astonishing
observation in this case is that peripheral blood counts
remained completely stable, and that the patient had
never required transfusions for now 43 treatment cycles
despite recurrence of del(7q) and karyotype evolution
with development of a second clone with monosomy 7.
Of the patients who achieved hematologic remission,
only three had somatic mitochondrial DNA mutations
suitable for follow-up. Two showed a CR (70→0→50%,
and 67→0%) and one had a PR (50→5%). Characteristics
of responders and patients with marrow remissions are
shown in Table 2. Tables 3 and 4 present an overview of
treatment details and responses.
Median number of cycles to response was 2 (range 1–9,
mean 4) but three patients needed 8 or 9 cycles. Median
responsedurationwas19months(4–42). Median survival was
9 months, 23 months for responders, 9 months for marrow
responders, and 7 months for non-responders (see Fig. 1a).
Potential factors influencing treatment response
Four patients received hydroxyurea (HU) for more than
1 cycle during their study treatment, due to leukocytosis
from start of study treatment. One of them had stable
disease, two were classified as having progressive disease,
and one patient remained stable until HU was discontinued.
The latter patient (no. 5) with CMML-II illustrates that HU
may influence the response to epigenetic treatment. He
started with a marrow blast count of 15% in March 2007,
which was virtually unchanged (18%) prior to cycle 5.
Regarding cytogenetics, 100% of mitoses (n=22) showed
trisomy 8. After 8 cycles, 1 cycle after HU had been stopped,
marrow blasts had decreased to 2%. Cells still harbored
trisomy 8 [18/18]. At the same time, platelet transfusion
dependency had subsided. After 12 cycles, the patient
achieved CgCR according to conventional cytogenetics and
BM-FISH (46, XY [24/24]) and PR by PB-CD34-FISH
and mitochondrial DNA monitoring. Apparently, study
treatment only became successful after HU had been
discontinued (see Discussion).
We analyzed other factors possibly related to response, as
shown in Table 5. There was no significant influence of age,
gender, IPSS, primary vs. secondary MDS, WBC, platelets,
and karyotype, although four out of seven patients (57%)
with chromosome 7 abnormalities responded, including two
with a complex karyotype. One further patient with
monosomy 7 and complex karyotype achieved a marrow
response. Factors negatively influencing response were
AML (vs. MDS), marrow blast count, pretreatment, and
transfusion dependency. Of the ten patients who had
received previous treatment, only one responded, while
8 out of 14 untreated patients (57%) in the entire group
and 7 out of 11 (64%) untreated MDS patients responded.
Variables influencing survival were AML (vs. MDS) and
transfusion dependency.
The influence of VPA serum levels was also evaluated.
Median VPA dosage was 25 mg/kg (14–41). The highest
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Clin Epigenet (2011) 2:389–399 393trough level was 86 μg/ml (58–122). Median VPA trough
level over the whole treatment period was 68 μg/ml (44–97),
due to necessary dose reductions. A serum level >70 μg/ml
was achieved after a median of 4 weeks. The likelihood of
responsewas influencedbymedian(p=0.004) and maximum
VPA levels (p=0.007). The time to reach a VPA level above
70 μg/ml also provided prognostic information (p=0.02).
The strongest predictive factor (p=0.00005) was the VPA
level achieved within the first 2–3 weeks of treatment. The
influence of median VPA serum levels on survival is
illustrated by Fig. 1c and Table 5. On the other hand, VPA
dosage (absolute amount or dose/kg) was not related to
response or survival. On multivariate analysis, median VPA
level was the only independent prognostic factor for
response (p=0.015), while MDS vs. AML (p=0.031) and
transfusion dependency (p=0.032) were the only indepen-
dent parameters influencing survival.
Side effects
Adverse events are summarized in Table 6. Most patients
had transient central nervous system (CNS) side effects,
necessitating dose reductions or temporary treatment
interruption in eight and cessation of therapy in two
patients. In one patient, Coombs-negative hemolysis
occurred. It remained unclear whether this was related
tooneofthestudydrugs.DiscontinuationofVPAwaswithout
effect,andhemolysisdidnotrespondtosteroids.Twopatients
developed a rash after AZA but were able to continue
treatment with concomitant steroids. Myelosuppression
occurred in all patients, especially during the initial
Table 3 Characteristics of response and treatment
Characteristic No. (range)
Cytologic CR/PR 7/2
Marrow response CMR/PMR 3/1
Hematologic improvement
HI-N 6
HI-P 9
HI-E 5
Cytogenetic response (conventional) CR/PR 6/0
FISH response (BM) CR/PR/not done 4/1/1
FISH response (CD34, pB)CR/PR 4/2
Mitochondrial mutations CR/PR 2/1
Median survival
All patients 9.5 months
Responders vs. marrow response vs.
nonresponders
23 vs. 9 vs.
7 months
Median number of cycles 5(2–43)
Median number of cycles to response 2(1–9)
Dose reduction vidaza 9
75% 5
50% 4
Median dosage VPA mg/kg 25 (14–41)
Maximum VPA level (median)/μg/ml 86 (58–122)
a
Median VPA level (median)/μg/ml 68 (44–97)
a
Median time to VPA level >70 μg/ml 4 weeks
b
Patients with significant VPA side effects leading to: 13
Dose reduction/Treatment break/cessation VPA 7/5/3
anot done, n=1
bnever acheived, n=1
Patient Cytologic
response (blast
count) (%)
Hematological
improvement
Cytogenetic
response
Response
FISH-BM
(%)
Response
FISH-CD34
(%)
Mito
response
(%)
F03 CRi HI-P CR nd CR na
D01 PR (5) HI-N, HI-P,
HI-E
nd nd nd nd
D03 CRdys HI-N, HI-P,
HI-E
na na na na
D04 CRdys HI-N, HI-P,
HI-E
CR CR CR na
D05 CR HI-N, HI-P CR CR PR (1) PR (5)
D06 CRdys HI-P CR CR PR (5) na
D14 CRdys None na na na na
D15 PR (5) HI-P, HI-E CR PR (6) CR CR
D17 CRdys HI-N, HI-P,
HI-E
CR CR CR CR
F02 SD (CMR) None na na na na
F05 SD (CMR) None None nd none na
D11 SD (CMR) None None none none None
D13 SD (PMR) None na na na None
Table 4 Response details
nd not done, na not applicable
394 Clin Epigenet (2011) 2:389–399cycles. Treatment had to be delayed in several patients
after the first or second cycle, and dose reductions of
AZA were made in seven cases. One patient died of
pneumonia after the first cycle.
Discussion
Our study of AZA plus VPA confirms that this combination
is feasible and efficacious with an ORR of 37% and a CR
rate of 29% in patients with higher-risk MDS and AML.
However, since our study was not randomized, the additive
value of VPA cannot be determined. AZA as monotherapy
significantly prolongs survival of patients with higher-risk
MDS (Fenaux et al. 2009). Still, about 50% of patients do
not respond, and response duration is limited despite
continued administration. In order to augment the effect of
AZA on epigenetic regulation of gene expression, the most
promising approach was to combine the demethylating
agent with an HDAC inhibitor (Yang et al. 2005).
Most combination studies to date have used VPA, which
requires higher concentrations than newer HDAC inhibitors
but is relatively selective for class-I-HDACs and leads to
degradation of HDAC 2 (Göttlicher et al. 2001). Protocols
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Fig. 1 Survival from start of treatment, a for the entire cohort, b responders vs. nonresponders, landmark analysis at 1 year (at 2 years, 44% of
responders are alive compared to 0% of non-responders) c) according to VPA serum level </≥70 μg/ml
Characteristics Responders
N=8
Nonresponders incl.
marrow CR N=16
p response
rate
p
survival
Median age 72 74 n.s. n.s.
a
Sex 78% male 80% male n.s. n.s.
Karyotype risk (IPSS) 44% high 53% high n.s. n.s.
Normal/abnormal KT 22% normal 33% normal n.s. n.s.
Chromosome 7 abnormality 44% Chr 7 27% Chr 7 n.s. n.s.
IPSS score 50% high 83% high n.s. n.s.
MDS vs. AML 89% MDS 33% MDS 0.02 0.0052
Prim vs. sek. 13% sek 33% sek n.s. n.s.
Treatment vs. no pretreatment 11% yes 60% yes 0.03 n.s.
Mean marrow blast count 15 40 0.009 n.s.
b
WBC/μl 3,000 3,900 n.s. n.s.
c
Transfusion dependency 56% 93% 0.047 0.014
Platelet count/μl 42 76 n.s. n.s.
d
Median VPA level (mean)/μg/ml 77 62 0.004 0.03
e
Maximum VPA level (mean)/μg/ml 101 80 0.007 0.040
f
Time to level >70 μg/ml 3 7 0.02 n.s.
g
VPA level week 2/3 79 46 0.00005 0.0012
h
VPA dosage (mg) 1,800 2,066 n.s. n.s.
i
VPA dosage/kg 23 27 n.s. n.s.
j
Table 5 Comparison of
characteristic responders vs.
non-responders and influence of
different characteristics on
response rate and survival
cutoff (=median):
a70 years
b20% marrow blasts
c3,500/μl
d60.000/μl
e70 μg/ml
f80 μg/ml
g5 weeks
h50 μg/ml
i2,000 mg
j25 mg/kg
Clin Epigenet (2011) 2:389–399 395vary considerably. All trials except ours added ATRA to the
treatment regimen, although Voso et al. (2009) did so only
in non- or suboptimal responders. Craddock et al. (2008)
added theophylline as a fourth substance. Various AZA
dosages have been used. In our trial, we chose a novel
dosing regimen for AZA (100 mg/m
2/day for 5 days) which
avoids the “weekend problem” while providing an overall
dose of AZA (500 mg/m
2/cycle) that is very similar to the
approved regimen (525 mg/m
2/cycle). The higher dose
intensity of AZA in our schedule may have contributed to
the increased myelosuppression compared to our previous
experience with AZA monotherapy. However, the combi-
nation with VPA, as well as unfavorable patient character-
istics, represent other potentially important factors. Two
previous studies (Soriano et al. 2007; Raffoux et al. 2010)
used a high-dose intermittent schedule for VPA. We chose
to apply VPA on a continuous schedule. The doses
administered by us and the serum trough levels achieved
were higher than in the Italian study (Voso et al. 2009).
Despite major differences in theses three treatment regimens,
the significant influenceofVPA serum levelsonresponse rate
and survival in our study was the same as that observed by
Soriano et al. and Voso et al. Also in line with previous
observations,wefoundnoinfluence ofVPAdosage,probably
due to pharmacogenomic differences between patients, as
suggested by Voso et al. (2009). As far as typical side effects
of HDAC inhibitors, like CNS or gastrointestinal symptoms
are concerned, we observed no increased incidence or
severity during combination treatment with AZA.
Combination trials have also been performed using
decitabine as a demethylating agent. A randomized trial
addingVPAintermittentlytodecitabineinoneofthetwoarms
(Issa et al. 2008) yielded response rates (52% vs. 43%) that
failed to show a statistically significant difference, probably
due to the limited number of patients included (n=67).
The overall response rate in our trial was 37%, which is
lower than expected from previous trials with AZA
monotherapy (Fenaux et al. 2009). However, our series
included a high proportion of AML patients, particularly
patients pretreated with intensive chemotherapy and/or
HDAC inhibitors. Although VPA can be beneficial for
patients with AML, the majority of patients included in the
abovementioned clinical trials had a relatively low marrow
blast count (Fenaux et al. 2009; Sudan et al. 2006). In
contrast, the French ATU program included 184 patients
with relapsed/refractory AML and generated a response rate
of only 13% (Itzykson et al. 2009). In our study, the
response rate according to IWG criteria was 57% for all
untreated patients (MDS and AML) and 64% for untreated
patients with MDS. The other combination trials mentioned
above reached comparable response rates. Phase II trials are
often difficult to compare, due to varying patient and
response characteristics, which are given in Table 7. For
example, Voso and coworkers decided to analyze responses
only in patients who completed 8 cycles. Some studies, in
contrast to our trial, classified marrow responses as
response rather than stable disease. Furthermore, IWG
criteria, which are currently considered the gold standard
for response evaluation, are different for MDS and AML.
A relatively large proportion of our patients achieved CR
(29% overall and 55% of previously untreated patients with
MDS). Hematological CR was accompanied by complete
cytogenetic remission in all evaluable cases. All long-time
hematologic improvements were associated with marrow
remissions, while not all marrow remissions produced
hematologic improvement. An improved CR rate with
combination therapy has been described in previous trials
(Soriano et al. 2007). Whether improved CR rates were due
to the addition of VPA, a slightly increased daily dosage of
AZA, or other causes is not entirely clear from these phase
II studies. The same is true for time to response, which
appeared shorter than with AZA monotherapy in the study
reported by Soriano et al. That observation is in accordance
with the median time to response in our trial (only 2 cycles).
However, even though combination therapy may achieve
earlier responses in a proportion of patients, it does not
seem to obviate the need for prolonged treatment. While
five of our patients responded quite early, after only 1 or
Table 6 Side effects 9 months 0.6%, 77.7% p=0.0038
Side effects grades 1/2 Frequency
Local skin reaction 25
Nausea 24
Diarrhea 19
Constipation 17
Leukocytosis 15
Fatigue 14
Hypokaliemia 13
Somnolence 12
Fever 10
Influenza-like symptoms 10
Side effects grade 3/4 Frequency
Neutropenic fever 12
Pneumonia 10
Febrile neutropenia 4
Septicemia 4
Dyspnea 3
Somnolence 3
Catheter-side infection 3
Neutropenia 3
Pancytopenia 3
Confusion 3
396 Clin Epigenet (2011) 2:389–3992 cycles, three other patients needed 8 or 9 cycles. Like
AZA monotherapy, combination therapy with AZA plus
VPA requires perseverance, and it is now generally
recommended that patients who achieve at least stable
disease should be kept on treatment as long as possible.
An interesting finding in our study was that patients can
remain transfusion-free with stable peripheral blood counts
despite showing a relapse in the bone marrow. We found that
increases in medullary blasts or aberrant cells may occur
without being followed by clinically relevant progression/
relapse. Actually, the two patients with the longest treatment
benefithadcytogenetic orevencytomorphologicalfull-blown
relapse. These findings illustrate that epigenetic treatment
may require changes in our concept of evaluating treatment
success. Achieving CR is not paramount, since it is not a
prerequisite for obtaining a substantial survival benefit. The
AZA-001 trial (Fenaux et al. 2010) made it clear that patients
whose best response was hematologic improvement had the
same increase in life expectancy as patients who achieved
CR or PR.
Even though a number of patients in our trial achieved
hematological CR, most of them showed persistent dys-
plastic features, as it is often the case after chemotherapy in
MDS as well. This was even true for patient 17, who was in
complete remission according to conventional cytogenetics,
PB-CD34-FISH, BM-FISH, and mitochondrial mutation
analysis. This patient relapsed relatively quickly after
16 cycles. This suggests that in some cases, the available
monitoringtoolsmaydetectonlythemostadvanced,dominant
MDS clone without revealing an underlying preleukemic
clone that may be responsible for the dysplastic features.
As in previous studies, favorable responses were
observed in patients with chromosome 7 abnormalities
(Raj et al. 2007). The response rate may not be better than
with a normal karyotype or trisomy 8, but this group of
patients is clearly doing worse with conventional therapies.
In contrast to Mufti et al. (2009), we even observed
responses in two of three patients who had chromosome 7
abnormalities as part of a complex karyotype (survival time
11 and 19 months, respectively).
An interesting aspect of our study relates to the possible
interaction of hydroxyurea with study medication. In
vitro studies suggest that inhibition of ribonucleotide
reductase by HU (Choi et al. 2007) interferes with
conversion of 5-azacytidine to 5-aza-2′-deoxycytidine,
thereby decreasing incorporation of the false nucleotide
into DNA and diminishing its hypomethylating effect.
AlthoughithasnotbeenproventhatDNAhypomethylationis
Table 7 Overview of different combination studies with VPA and AZA
Patient This study Soriano et al. Voso et al. Raffoux et al. Craddock et al.
Drugs VPA, 5-Aza VPA, Aza, ATRA VPA, Aza, ATRA
a VPA, Aza, ATRA VPA, Aza, ATRA,
theophylline
Dosage VPA Median dosage 25 mg/kg
continuously
50–75 mg/kg 7 days 600–1,500 mg
continuously
35–50 mg/kg 7 days ng
Dosage AZA 100 mg/m
2 5 days 75 mg/m
2 7 days 75 mg/m
2 7 days 75 mg/m
2 7 days 75 mg/m
2 5 days
No. of pts. n=25, evaluable 24 n=53 n=62, 26
evaluable
b
n=65 n=45
Median age 73 years 69 years 70 years 72 years 66 years
No. AML/MDS 75%/25%
c 92%/8% 31%/69%
d 85%/15% 80%/20%
Pretreatment n=10 (42%) n=20 (38%) ng n=13 (20%) n=30 (67%)
ORR 37% 27%
e 31% 26% 33%
CR/PR/HI/
marrow
response
7/2/0/4 27/0/0/7 3/5/4/ng 14/3/ng
f/ng 7/8/ng/ng
Median cycles to
response
2( 1 –9) 2 (1–3) 5 (2–10) months
g ng 2 (1–6)
OS 9 months (23 in
responders)
6.5 months (14+ in
responders)
14.4 months 12.4 months (19.5 in
responders)
ng
ng not given
aonly in non-responders
bat least 8 cycles to be evaluable
c46%/54% according to FAB
d100% according to FAB
e42% including marrow response
f12.5% of non-responders had HI-erythroid
gTime to CR
Clin Epigenet (2011) 2:389–399 397the only mechanism behind the clinical efficacy of AZA, the
clinical course of our patient who achieved remission only
after cessation of HU appears to underscore the relevance of
HU interference with AZA conversion, thus pointing to the
importanceofAZAgettingincorporatedintoDNA.Itisworth
mentioning that three further patients who received HU
during study treatment were non-responders.
Our trial was the first to investigate the combination of
AZA plus VPA without additional ATRA. Although the
response rate was not higher than would be expected with
AZA monotherapy, the heterogeneity of the patient popula-
tion, witha significant proportion ofpretreatedAML patients,
shouldbetakenintoconsideration.TheCRratewasfavorable
compared with previously published trials, and some of the
responses appeared to occur faster than with single-agent
AZA. These observations as well as the significant influence
of VPA serum levels on response suggest that the HDAC
inhibitor contributes to treatment success. However, the true
value of HDAC inhibitors in this kind of epigenetic
combination therapy can only be determined by randomized
trials.
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